This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / UniQure Faces Securities Class Action Lawsuit
Regulatory class action lawsuit

UniQure Faces Securities Class Action Lawsuit

Analysis based on 8 articles · First reported Feb 11, 2026 · Last updated Mar 09, 2026

Sentiment
-20
Attention
2
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The class action lawsuit against UniQure is likely to negatively impact its stock price due to investor concerns over alleged misrepresentations and potential financial liabilities. For the legal industry, particularly firms like Bronstein, Gewirtz & Grossman, LLC, such lawsuits represent business opportunities.

Biotechnology Legal Services
Event Summary

A class action lawsuit has been filed against UniQure N.V. by Bronstein, Gewirtz & Grossman, LLC, on behalf of investors who purchased UniQure securities between September 24, 2025, and October 31, 2025. The lawsuit alleges that UniQure and its officers made materially false and misleading statements regarding the design of its Pivotal Study and the approval status from the United States===Food and Drug Administration (FDA). Specifically, the complaint claims that UniQure downplayed the necessity of additional studies, which could delay its Biologics License Application (BLA) submission, thereby lacking a reasonable basis for its public statements about business operations and prospects.

Key Actions
100 Bronstein, Gewirtz & Grossman, LLC filed a class action lawsuit UniQure
90 UniQure made materially false and/or misleading statements
Entities Involved
stock
UniQure
UniQure is facing a class action lawsuit for allegedly making materially false and/or misleading statements regarding its Pivotal Study design and the likelihood of delaying its Biologics License Application (BLA) timeline. This could negatively impact its stock price and reputation.
Importance 100 Sentiment -50
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is the law firm that filed the class action lawsuit against UniQure, seeking to recover damages for investors. This action is central to their business model of representing investors in securities fraud class actions.
Importance 80 Sentiment 50
per
Peretz Bronstein
Peretz Bronstein is a founding partner of Bronstein, Gewirtz & Grossman, LLC, and is involved in the class action lawsuit against UniQure. His firm aims to restore investor capital and ensure corporate accountability.
Importance 60 Sentiment 40
per
Nathan Miller
Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, and is a contact person for investors interested in joining the UniQure class action lawsuit.
Importance 40 Sentiment 30
govactor
United States===Food and Drug Administration
The United States===Food and Drug Administration's (FDA) approval process for UniQure's Pivotal Study design and BLA timeline is a key point of contention in the lawsuit, as UniQure allegedly misrepresented the FDA's stance.
Importance 30 Sentiment 0
Relationships
Bronstein, Gewirtz & Grossman, LLC related ↔ UniQure
Peretz Bronstein related ↔ Bronstein, Gewirtz & Grossman, LLC
Nathan Miller related ↔ Bronstein, Gewirtz & Grossman, LLC
United States===Food and Drug Administration related ↔ UniQure
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.